Cargando…
Efinaconazole in the treatment of onychomycosis
Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-derm...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459619/ https://www.ncbi.nlm.nih.gov/pubmed/26082652 http://dx.doi.org/10.2147/IDR.S69596 |
| _version_ | 1782375246346584064 |
|---|---|
| author | Lipner, Shari R Scher, Richard K |
| author_facet | Lipner, Shari R Scher, Richard K |
| author_sort | Lipner, Shari R |
| collection | PubMed |
| description | Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis. |
| format | Online Article Text |
| id | pubmed-4459619 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Dove Medical Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-44596192015-06-16 Efinaconazole in the treatment of onychomycosis Lipner, Shari R Scher, Richard K Infect Drug Resist Review Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis. Dove Medical Press 2015-06-01 /pmc/articles/PMC4459619/ /pubmed/26082652 http://dx.doi.org/10.2147/IDR.S69596 Text en © 2015 Lipner and Scher. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| spellingShingle | Review Lipner, Shari R Scher, Richard K Efinaconazole in the treatment of onychomycosis |
| title | Efinaconazole in the treatment of onychomycosis |
| title_full | Efinaconazole in the treatment of onychomycosis |
| title_fullStr | Efinaconazole in the treatment of onychomycosis |
| title_full_unstemmed | Efinaconazole in the treatment of onychomycosis |
| title_short | Efinaconazole in the treatment of onychomycosis |
| title_sort | efinaconazole in the treatment of onychomycosis |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459619/ https://www.ncbi.nlm.nih.gov/pubmed/26082652 http://dx.doi.org/10.2147/IDR.S69596 |
| work_keys_str_mv | AT lipnersharir efinaconazoleinthetreatmentofonychomycosis AT scherrichardk efinaconazoleinthetreatmentofonychomycosis |